Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Clarus Therapeutics, Inc.
With
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Determination of the steady-state serum T pharmacokinetic profiles for two oral formulations of T-esters \[testosterone undecanoate (TU) and TU combined with testosterone enanthate (TE)\] administered bis in die (BID) to 29 hypogonadal adult male subjects. TU was evaluated in total daily doses of 400 and 600 mg equivalents of T given twice daily for 7 or 8 days; TU + TE was evaluated in total daily doses of 600 and 800 mg equivalents of T given twice daily for 7 days. All subjects were enrolled into a single group and proceeded through the four Treatment Periods 1-4 in a sequential manner. In Treatment Period 3 the effect of food on the study-state pharmacokinetics profile of the TU formulation was evaluated.
Age
18–68
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male, ages 18-68
Serum total T less than or equal to 275 ng/dL
You may not be if
Significant intercurrent disease of any type, in particular, liver, kidney or heart disease, uncontrolled diabetes mellitus or psychiatric illness.
Abnormal prostate digital rectal examination, elevated prostate-specific antigen (PSA), American Urological Association (AUA) symptom score of \>15, and/or history of prostate cancer.
Hematocrit of \<35 or \>50%
Body mass index (BMI) \>36
Serum transaminases \> 2 times upper limit of normal or serum bilirubin \> 2.0 mg/dL
